Skip to main content
Premium Trial:

Request an Annual Quote

Scienion to Supply Protagen with Microarray Batches for Clinical Validation of Protein Biomarkers

Premium

Scienion said this week that it will provide protein microarray batches of more than 1,000 arrays to Protagen for that company's clinical validation studies of its protein biomarker panels.

According to Protagen chief scientific officer Peter Schulz-Knappe, the microarray batches will be used in "multicenter, clinical validation studies" of the company's protein biomarker panels for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer.

Additionally, the two Dortmund, Germany-based firms will collaborate under a strategic partnership to evaluate new platforms for multiplex analytics and develop new techniques that they will carry through jointly to the proof-of-concept stage.

"Scienion's sciFlexArrayer technology allows the manufacturing of protein microarray batches each with more than 3,500 single proteins in highest quality and reproducibility," Schulz-Knappe said in a statement. "Thereby, we can realize the needed consistency in quality and properties throughout three stages: from spot to spot, from array to array, and from batch to batch."

Financial and other terms of the agreement were not disclosed.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.